Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches

Continuous development of personalized treatments is undoubtedly beneficial for oncogenic patients’ comfort and survival rate. Mutant TP53 is associated with a worse prognosis due to the occurrence of metastases, increased chemoresistance, and tumor growth. Currently, numerous compounds capable of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Roszkowska, Katarzyna A., Piecuch, Aleksandra, Sady, Maria, Gajewski, Zdzisław, Flis, Sylwia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654280/
https://www.ncbi.nlm.nih.gov/pubmed/36362074
http://dx.doi.org/10.3390/ijms232113287
_version_ 1784828891091697664
author Roszkowska, Katarzyna A.
Piecuch, Aleksandra
Sady, Maria
Gajewski, Zdzisław
Flis, Sylwia
author_facet Roszkowska, Katarzyna A.
Piecuch, Aleksandra
Sady, Maria
Gajewski, Zdzisław
Flis, Sylwia
author_sort Roszkowska, Katarzyna A.
collection PubMed
description Continuous development of personalized treatments is undoubtedly beneficial for oncogenic patients’ comfort and survival rate. Mutant TP53 is associated with a worse prognosis due to the occurrence of metastases, increased chemoresistance, and tumor growth. Currently, numerous compounds capable of p53 reactivation or the destabilization of mutant p53 are being investigated. Several of them, APR-246, COTI-2, SAHA, and PEITC, were approved for clinical trials. This review focuses on these novel therapeutic opportunities, their mechanisms of action, and their significance for potential medical application.
format Online
Article
Text
id pubmed-9654280
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96542802022-11-15 Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches Roszkowska, Katarzyna A. Piecuch, Aleksandra Sady, Maria Gajewski, Zdzisław Flis, Sylwia Int J Mol Sci Review Continuous development of personalized treatments is undoubtedly beneficial for oncogenic patients’ comfort and survival rate. Mutant TP53 is associated with a worse prognosis due to the occurrence of metastases, increased chemoresistance, and tumor growth. Currently, numerous compounds capable of p53 reactivation or the destabilization of mutant p53 are being investigated. Several of them, APR-246, COTI-2, SAHA, and PEITC, were approved for clinical trials. This review focuses on these novel therapeutic opportunities, their mechanisms of action, and their significance for potential medical application. MDPI 2022-10-31 /pmc/articles/PMC9654280/ /pubmed/36362074 http://dx.doi.org/10.3390/ijms232113287 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Roszkowska, Katarzyna A.
Piecuch, Aleksandra
Sady, Maria
Gajewski, Zdzisław
Flis, Sylwia
Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
title Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
title_full Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
title_fullStr Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
title_full_unstemmed Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
title_short Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
title_sort gain of function (gof) mutant p53 in cancer—current therapeutic approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654280/
https://www.ncbi.nlm.nih.gov/pubmed/36362074
http://dx.doi.org/10.3390/ijms232113287
work_keys_str_mv AT roszkowskakatarzynaa gainoffunctiongofmutantp53incancercurrenttherapeuticapproaches
AT piecuchaleksandra gainoffunctiongofmutantp53incancercurrenttherapeuticapproaches
AT sadymaria gainoffunctiongofmutantp53incancercurrenttherapeuticapproaches
AT gajewskizdzisław gainoffunctiongofmutantp53incancercurrenttherapeuticapproaches
AT flissylwia gainoffunctiongofmutantp53incancercurrenttherapeuticapproaches

Ejemplares similares